Tenax Therapeutics (TENX) Receivables - Net (2011 - 2018)
Tenax Therapeutics recorded quarterly Receivables - Net of $39286.0 in Q2 2018, little changed quarter-over-quarter from $39286.0 in Q1 2018, and up 59.38% year-over-year from $24649.0 in Q2 2017.
Tenax Therapeutics' Receivables - Net history runs 8 years deep, the most recent figure standing at $39286.0 for Q2 2018.
- In Q2 2018, Receivables - Net rose 59.38% year-over-year to $39286.0; the TTM figure through Jun 2018 stood at $39286.0 (up 59.38% YoY), while the FY2017 annual figure was $50171.0, down 30.89% from the prior year.
- Receivables - Net came in at $39286.0 for Q2 2018 at Tenax Therapeutics, roughly flat from $39286.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $76475.0 in Q2 2015 to a low of $24648.0 in Q2 2016.
- A 5-year average of $45564.6 and a median of $39286.0 in 2018 frame the typical range for Receivables - Net.
- On a YoY basis, Receivables - Net climbed as much as 289.28% in 2014 and fell as far as 91.83% in 2014.
- Tenax Therapeutics' Receivables - Net stood at $36358.0 in 2014, then jumped by 36.0% to $49448.0 in 2015, then surged by 46.82% to $72599.0 in 2016, then sank by 30.89% to $50171.0 in 2017, then dropped by 21.7% to $39286.0 in 2018.
- According to Business Quant data, Receivables - Net over the past three periods registered $39286.0, $39286.0, and $50171.0 for Q2 2018, Q1 2018, and Q4 2017 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 39,286.00 |
| Jun 30, 2018 | 39,286.00 |
| Mar 31, 2018 | 39,286.00 |
| Mar 31, 2018 | 39,286.00 |
| Dec 31, 2017 | 50,171.00 |
| Dec 31, 2017 | 50,171.00 |
| Sep 30, 2017 | 24,649.00 |
| Sep 30, 2017 | 24,649.00 |
| Jun 30, 2017 | 24,649.00 |
| Jun 30, 2017 | 24,649.00 |
| Mar 31, 2017 | 24,649.00 |
| Mar 31, 2017 | 24,649.00 |
| Dec 31, 2016 | 72,599.00 |
| Dec 31, 2016 | 72,599.00 |
| Sep 30, 2016 | 72,600.00 |
| Sep 30, 2016 | 72,600.00 |
| Jun 30, 2016 | 24,648.00 |
| Jun 30, 2016 | 24,648.00 |
| Mar 31, 2016 | 49,297.00 |
| Mar 31, 2016 | 49,297.00 |
| Dec 31, 2015 | 49,448.00 |
| Dec 31, 2015 | 49,448.00 |
| Apr 30, 2015 | 76,475.00 |
| Apr 30, 2015 | 76,475.00 |
| Jan 31, 2015 | 64,662.00 |
| Jan 31, 2015 | 64,662.00 |
| Oct 31, 2014 | 36,358.00 |
| Oct 31, 2014 | 36,358.00 |
| Jul 31, 2014 | 36,358.00 |
| Jul 31, 2014 | 36,358.00 |
| Apr 30, 2014 | 36,358.00 |
| Apr 30, 2014 | 36,358.00 |
| Jan 31, 2014 | 53,106.00 |
| Jan 31, 2014 | 53,106.00 |
| Oct 31, 2013 | 64,815.00 |
| Oct 31, 2013 | 64,815.00 |
| Jul 31, 2013 | 96,786.00 |
| Jul 31, 2013 | 96,786.00 |
| Apr 30, 2013 | 445,237.00 |
| Apr 30, 2013 | 445,237.00 |
| Jan 31, 2013 | 13,642.00 |
| Jan 31, 2013 | 13,642.00 |
| Oct 31, 2012 | 17,193.00 |
| Oct 31, 2012 | 17,193.00 |
| Jul 31, 2012 | 23,632.00 |
| Jul 31, 2012 | 23,632.00 |
| Apr 30, 2012 | 13,385.00 |
| Apr 30, 2012 | 13,385.00 |
| Jan 31, 2012 | 19,400.00 |
| Jan 31, 2012 | 19,400.00 |
| Oct 31, 2011 | 7,559.00 |
| Oct 31, 2011 | 7,559.00 |
| Jul 31, 2011 | 28,119.00 |
| Jul 31, 2011 | 28,119.00 |
| Apr 30, 2011 | 138,867.00 |
| Apr 30, 2011 | 138,867.00 |